Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
EU strikes landmark deal to rewrite its drug rulebook

EU strikes landmark deal to rewrite its drug rulebook

Rule Changes

A 32‑month fight over how long big pharma can keep rivals out of Europe's medicine cabinets

December 19th, 2025: EMA Executive Director Emer Cooke hails pharma package as 'historic milestone'

Overview

After two years of trench warfare between EU governments, lawmakers and drug makers, Brussels has finally agreed a 'pharma package' that tears up the bloc's 20‑year‑old drug rules. The package locks in eight years of data protection, one year of market exclusivity, and bonuses extending to 11 years if companies meet public‑health goals.

At stake is who pays and who profits. Patients and health systems want cheaper, faster access to drugs, while industry warns shorter exclusivity will chase research money to the US and Asia. The package arms governments to demand adequate supplies of key medicines, lets generics prepare for day‑one launch, and dangles a controversial voucher to coax companies to develop badly needed antibiotics.

Play on this story Voices Debate Who Said What? Predict

Key Indicators

8+1 to 11 years
New protection window for innovative drugs
Baseline eight years of data plus one year of market protection, extendable to a maximum of eleven.
€490m
Antibiotic voucher revenue cap
High‑earning products above this annual sales level cannot use the transferable exclusivity voucher.
136
Critical medicines in shortage (2022–2024)
Number of critical shortages flagged by EU auditors, driving urgency for reform.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

Play

Exploring all sides of a story is often best achieved with Play.

Log in to play. Track your picks, climb the leaderboards. Log in Sign Up
Predict 3 ways this could play out. Contrarian picks score more — points lock when the scenario resolves. Log in to play
Timeline Five events from this story — drag them oldest to newest. Log in to play
Connections Sixteen names from the news. Find the four hidden groups of four. Log in to play

People Involved

Sophie Løhde
Sophie Løhde
Claims the deal balances industry innovation with faster patient access and stronger supply security
 Tiemo Wölken
Tiemo Wölken
Key Parliament architect of the final compromise on incentives and access
 Stella Kyriakides
Stella Kyriakides
Oversaw the original reform proposal and welcomed the political agreement as a ‘generational’ change
 Nathalie Moll
Nathalie Moll
Leading industry critic of the reform, warning it weakens Europe’s competitiveness
 Emer Cooke
Emer Cooke
Welcomed the pharma package as a historic milestone and opportunity for regulatory modernization

Organizations Involved

Council of the European Union
Council of the European Union
EU Legislative Body
Co-legislator representing member states; pushed hard on supply obligations and antibiotic incentives

The Council gathers national ministers who must agree common positions before any EU law can pass.
European Parliament
European Parliament
EU legislative body
Co-legislator; pushed to soften cuts to exclusivity while tightening access rules

Parliament represents EU citizens and can amend or block legislation, including drug‑industry rules.
European Commission
European Commission
Supranational antitrust authority
Originator of the pharma package and parallel Critical Medicines Act proposals

The Commission drafts EU laws and polices their implementation, including pharmaceutical rules.
European Federation of Pharmaceutical Industries and Associations (EFPIA)
European Federation of Pharmaceutical Industries and Associations (EFPIA)
Industry association
Leads lobbying against perceived weakening of IP and incentives in the new rules

EFPIA is the main lobby group for Europe’s research‑based pharmaceutical companies.
European Medicines Agency (EMA)
European Medicines Agency (EMA)
EU Regulatory Body
Preparing to implement streamlined structures and faster review processes under the new pharma package

EMA is the EU's central drug regulator, responsible for scientific evaluation of medicines and oversight of the bloc's authorization system.

Timeline

November 2020 December 2025

9 events Latest: December 19th, 2025 · 5 months ago
Tap a bar to jump to that date

  1. EMA Executive Director Emer Cooke hails pharma package as 'historic milestone'

    Latest Institutional

    EMA's executive director releases year‑end statement calling the December 11 agreement a 'golden opportunity' for medicines regulation to become more agile and efficient, and highlighting it as a chief accomplishment of the agency's 30th anniversary year.

  2. Council and Parliament strike provisional pharma package deal

    Negotiation

    After overnight trilogues, negotiators agree on eight years’ data protection plus one year of market protection, extendable to eleven years if firms meet conditions on unmet needs, clinical benefit and multi‑country trials. The deal retains Article 56a supply obligations, broadens the Bolar exemption so generics can prepare tenders before patent expiry, and creates a transferable one‑year exclusivity voucher for priority antibiotics with a €490 million revenue cap.

  3. EU auditors warn of record medicine shortages

    Oversight

    The European Court of Auditors reports 136 critical medicine shortages between 2022 and late 2024, criticising weak EU coordination and giving new political urgency to supply‑focused reforms, including Article 56a.

  4. Council agrees its mandate on the pharma package

    Council

    EU governments back eight years of data protection, keep a strong Article 56a allowing states to require sufficient supplies of protected medicines, and endorse an antibiotic voucher with a blockbuster revenue cap.

  5. Commission proposes Critical Medicines Act

    Policy

    In response to chronic shortages, the Commission unveils a Critical Medicines Act to boost EU manufacturing and joint procurement, underscoring the supply‑security backdrop to the pharma package talks.

  6. European Parliament adopts its negotiating position

    Parliament

    Parliament formally adopts its position on the pharma package, backing longer minimum protection than the Commission wanted but demanding stricter rules on access, shortages and environmental impacts.

  7. Parliament committee softens cuts to exclusivity

    Parliament

    MEPs in the health committee back a compromise baseline of around 7.5 years’ data protection with scope for up to roughly 11.5 years’ total exclusivity, easing industry concerns about the original six‑year plan.

  8. Commission proposes sweeping ‘pharma package’ reform

    Legislative Proposal

    The Commission publishes a new directive and regulation cutting baseline data protection to six years, creating a ladder of extra exclusivity linked to unmet needs and broad launches, and proposing an antibiotic incentive voucher.

  9. EU launches Pharmaceutical Strategy after COVID exposes shortages

    Policy

    The European Commission unveils a Pharmaceutical Strategy for Europe, promising a full legislative overhaul to improve access, affordability and supply security after pandemic‑era drug shortages.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

1984–1990s

Hatch‑Waxman Act Reshapes the US Drug Market

The 1984 US Drug Price Competition and Patent Term Restoration Act, better known as Hatch‑Waxman, created data exclusivity for brand‑name drugs while allowing generics to rely on innovator data via abbreviated applications. It also formalised the ‘Bolar’ research exemption and 180‑day exclusivity for the first generic challenger, unleashing a wave of generic entry once patents and exclusivities expired.

Then

Brand‑name firms gained clearer protection and patent‑term restoration, while generic competition sharply cut prices after exclusivity ended.

Now

Hatch‑Waxman became the template for balancing innovation and access, influencing later EU rules on data protection and Bolar exemptions.

Why this matters now

The EU’s pharma package is a new attempt at the same balancing act—rewarding innovation while turbo‑charging day‑one generic entry.

2005–2023

EU’s 8+2+1 Exclusivity Regime for Medicines

From the mid‑2000s, EU law gave new medicines eight years of data exclusivity plus two years of market protection, with a possible extra year for valuable new indications. This ‘8+2+1’ formula harmonised protection across member states and often extended commercial monopolies well beyond underlying patent life.

Then

The regime offered strong predictability for innovators but delayed generic entry and fuelled complaints about drug costs.

Now

Over time, it fed perceptions that Europe over‑rewarded old blockbusters while still losing new R&D to other regions.

Why this matters now

The new pharma package is effectively a renegotiation of 8+2+1, keeping much of the protection but tying benefits more tightly to public‑health goals.

2018–2019

EU SPC Manufacturing Waiver and Stockpiling Reform

The EU amended its Supplementary Protection Certificate rules to let EU‑based generics and biosimilars manufacture SPC‑protected drugs for export and stockpile them during the last six months of protection. The goal was to allow ‘day‑one’ launches in Europe and restore competitiveness against manufacturers in jurisdictions without SPC‑style extensions.

Then

Generic producers gained new manufacturing opportunities, while originators warned of erosion of effective exclusivity.

Now

The waiver signalled a gradual policy tilt toward earlier competition and laid legal groundwork for broader Bolar‑style exemptions.

Why this matters now

The pharma package’s expanded Bolar exemption and focus on day‑one entry are the next step in this trend toward earlier, structured generic competition.

Sources

(25)
+19
Council of the European Union Reuters Euronews European Commission European Parliament European Commission EFPIA Intellectual Property Office of Ireland Wikipedia European Medicines Agency Pharmaceutical Technology Sidley Austin LLP Jones Day Cooley LLP A&O Shearman Baker McKenzie European Pharmaceutical Review Council of the European Union Reuters Euronews Reuters European Commission Euronews European Medicines Agency European Parliament